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Are provided with this legislatively-mandated, medically and factually accurate MDPH Commissioner 
approved EC provider fact sheet titled Key Facts About Emergency Contraception: For Emergency 
Department Staff that Provide Care to Sexual Assault and Rape Survivors, available online at  
www.mass.gov/emergencycontraception.
Promptly provide the legislatively-mandated, medically and factually accurate MDPH Commissioner-
approved EC patient fact sheet titled Five Key Facts about Emergency Contraception: For Survivors of Sexual 
Assault to every survivor who presents to the ED after a rape. This EC patient fact sheet is available in the 
Massachusetts Sexual Assault Evidence Collection Kit (MSAECK) in English, and online in English, Spanish, 
Portuguese, and Haitian-Creole at www.mass.gov/emergencycontraception. If this fact sheet is 
unavailable in the patient’s preferred language, use a competent medical interpreter to translate it instead.  
Promptly offer EC to each survivor and initiate a full course of EC medication (and not only a written 
prescription) in the ED upon her request. 
Understand that they are prohibited from requiring any survivor to complete any part of a sexual 
assault evidence collection kit or a police report as a condition of receiving any of the above.
Document the offer of EC information and EC medication in the patient’s medical record and ensure 
that any contraindications to EC resulting in the denial of EC access to a survivor who presents for care in 
the ED are documented in her medical record and based on best clinical practice.  
Complete the MSAECK Form 2A: Provider Sexual Crime Report (PSCR) ‘Emergency 
Contraception Report’ (checkbox) located in the mandatory reporting section of the anonymous 
PSCR for each assault case reported in the ED: 
70E Emerg. Contraception Administered:    Yes    Not indicated    Declined    Not offered
 •The anonymous Emergency Contraception Report must be completed for each assault case reported 
in the ED, whether or not EC was indicated or administered. A copy of the PSCR may also be found at 
www.mass.gov/emergencycontraception.
Ensure that the fully completed mandatory, anonymous PSCR is promptly faxed to the  
Executive Office of Public Safety at 617-725-0260, and to the local public safety authority in the  
town where the assault occurred. 
Provide a notice of patient rights as required by M.G.L. c. 111, § 70E, as amended by Chapter 91A.
Do not interfere with hospital compliance with the law, regardless of their personal values or beliefs,  
by instituting systems to ensure that 24 hours a day, 7 days a week all survivors are promptly provided  
full rights under M.G.L. c. 111, § 70E.
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Massachusetts General Law c. 111, § 70E codifies the rights of female rape victims of childbearing 
age to receive timely access to EC in the Emergency Department (ED). To comply with this law, acute 
care hospitals must provide this legislatively-mandated fact sheet prepared by the Commissioner of Public 
Health to all ED staff that provide care to female rape victims of childbearing age who present to the ED 
(survivors) and fulfill all of the requirements described herein.
Under the law, all acute care hospital EDs must ensure that staff providing care  
to survivors:
!
After reviewing this fact sheet, please address any questions to a supervisor, or 
contact the MDPH Family Planning Program for additional information, support, or 
technical assistance at: www.mass.gov/emergencycontraception or 617-624-6060.
A recent study suggests that more research is needed to determine the potential impact of BMI/weight on 
EC efficacy.6,8 For women with a BMI of 26 or over who used progestin-only EC, pregnancy rates were no 
different than if they had not used EC at all. Ulipristal acetate (ella®) appeared to decline in efficacy at a higher 
BMI threshold of 35, suggesting that the most highly effective method for obese women is the copper IUD. 
Increasing the dose of EC pills for overweight or obese women has not been studied and is not currently 
recommended.6,8 Helpful FAQs on weight and EC efficacy have been prepared by www.rhtp.org and  
www.not-2-late.com.
Women who are overweight or obese should not be denied their right to access EC pill regimens in 
the ED today, although they may also wish to consider emergency copper IUD insertion as soon as 
possible to maximize pregnancy prevention after sexual assault or rape (see page 3).   
EC pill contraindications and side effects
Contraindications:
 •Known or suspected pregnancy reported  
by the patient.1,2,9,10
Side Effects: 
 •Side effects are mild and few adverse events have  
been reported.1,5
 •Some women may experience nausea and vomiting,  
and may be given anti-emetic medication preventively.1,2  
These symptoms are more common with combined oral 
contraception pills (OCPs) than with FDA-approved EC 
products. 
 •Other side effects may include short-term fatigue, 
headache, dizziness, lower abdominal pain, or a change in 
the timing or flow of the next menstrual cycle.9,10
EC is a safe and effective way to prevent 
pregnancy after sexual assault or rape.1-8  
Taking EC as soon as possible significantly decreases a 
woman’s chances of becoming pregnant from the assault. It 
is an important part of your role as an ED provider to provide 
medically accurate information about and prompt access to 
EC in the ED post-sexual assault, to ensure that the standard of 
care is met for all survivors.
What is EC?  
EC regimens were first described in 1974 by doctors 
prescribing special doses of birth control pills to prevent 
pregnancy after rape. A dedicated product became available 
in 1998. Although EC has been safely and widely used by 
women seeking to prevent unintended pregnancy for over 
thirty years, public awareness remains low.1,2 Therefore, it is 
especially important to inform survivors about EC.2,6
How do EC pills work?
 •As with regular daily birth control pills, EC pills prevent 
pregnancy by delaying or inhibiting ovulation.1,2,5,6,9-11
 •Recent reports state that EC pills do not interfere with 
the development or implantation of a fertilized  
egg.6,12 No direct clinical evidence supports the theory that 
EC pills inhibit fertilization and prevent implantation  
of the fertilized egg.1,2,5,6
 •EC will only work to prevent pregnancy if a woman  
is not already pregnant. EC will not interfere  
with an established pregnancy and will not  
cause spontaneous abortion or miscarriage.1,2,5,6
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Medically and factually accurate information on Emergency Contraception (EC) pills:
Note: Use of EC pills is not contraindicated in 
women whose pregnancy status is unknown. A 
pregnancy test is not required before EC can be 
administered,1,2,6,13,14 although it is recommended 
prior to choosing ella® (refer to the product’s 
package insert for details).9,10
If a patient does not consent to a pregnancy test, 
she should still be offered information on EC, as 
there are no restrictions for use in cases of rape 3,4 
and Massachusetts law requires hospitals to offer 
and initiate EC upon request for all survivors.13,14 
	 						Potential	Impact	of	BMI/Weight	on	EC	Efficacy!
Emergency copper IUD insertion may be clinically indicated as EC for women with a high 
BMI.6,8 
ED staff are mandated to provide information about and acess to EC in the ED so that rape survivors have timely acess  
to the most highly effective pregnancy prevention methods. As emerging data now suggest that both ulipristal acetate 
and progestin-only pills rapidly decline in efficacy with increasing body mass index (BMI),6,8 it is important for EDs to 
provide, at a minimum, information about and access to more highly effective EC methods, including emergency 
copper IUD insertion.
Emergency copper IUD insertion may not be:
 •currently or consistently available in all ED settings, or
 •clinically indicated at time of visit (due to active trauma or STI infection), or 
 •immediately appealing to many recent survivors of sexual assault or rape.
However, as the average American woman weighs 166 pounds, ED staff should be able to provide supportive referrals 
for emergency IUD insertion to facilitate access (see box below).
Intra-uterine contraceptive device (IUD): The copper IUD is 99.9% effective at preventing 
pregnancy for up to 5 days after sexual assault or rape, and provides a highly efficacious, immediate, and 
cost-effective ongoing birth control method for up to 10 years post-insertion.1,2,6
Pregnancy rates following copper IUD insertion are extremely low in comparison to any EC pill regimen, and remain 
at 0.1% since having been introduced in 1976. Hormonal IUDs have not been studied and are not recommended for 
use as EC.6
 •Preliminary data suggests that when clinically indicated, emergency insertion of the copper IUD is 
probably the best EC choice for obese women.6,8
Like EC pills, the copper-bearing IUD works primarily by inhibiting fertilization, however post-coital insertion also 
may prevent the implantation of a fertilized egg.2,15
 •Use of a copper IUD is not associated with an increased risk of tubal infertility.6,15
Clinical guidelines for emergency IUD insertion,1, 2 including in the context of sexual assault7,15 are available at  
www.mass.gov/emergencycontraception.
 •Research indicates that the presence of STI infection, not the placement of an IUD, increases PID risk.15 
Therefore, current ACOG guidelines2 allow STI screening and IUD insertion on the same day, even for women 
presenting after rape,7,15 as an asymptomatic chlamydia or gonorrhea infection may be treated with the IUD  
in place.2,15
 
The most effective type of EC is emergency copper IUD insertion within 5 days after 
sexual assault or rape.1, 2, 6  
*
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Helping survivors access emergency copper IUD insertion
Women who are interested in scheduling an emergency IUD insertion should not be denied the right to receive 
EC pills in the ED and should be offered or referred for emergency IUD insertion as soon as possible. 
A supportive referral for IUD insertion may be provided to a nearby MDPH Family Planning Program  
by contacting 617-624-6060 or www.mariatalks.com/find-services.
Rape Crisis Centers can also provide medical advocacy for survivors in need of timely medical appointments 
and other ongoing services. Call 1-800-841-8371 or visit www.surviverape.com.
!
Ulipristal Acetate pills: ella® is an EC pill that contains ulipristal acetate, a medicine that was FDA-approved in 
2010 after being available in Europe for several years. It is available by prescription.
The FDA has approved ulipristal acetate EC pills to be initiated up to 120 hours (5 days) after unprotected 
sex (or sexual assault).10  
Ulipristal acetate is considered the most effective medication available for preventing pregnancy after 
unprotected sex because it is statistically more effective than progestin-only pills throughout all 
120 hours (5 days).6,11  
 •Use of ulipristal acetate has been shown to result in up to 65% lower pregnancy rates following the use 
of progestin-only pills when administered in the first 24 hours, and up to 42% lower rates up  
to 72 hours after unprotected sex.6
 •Ulipristal acetate can prevent more pregnancies once the leading follicle has reached a larger size  
and ovulation is about to occur.6,11
Unlike progestin-only EC, the efficacy of ulipristal acetate does not decline throughout the 5 days 
following unprotected sex. In part, this is because ulipristal acetate is able to prevent follicular rupture at a 
later stage of follicular development than progestin-only pills.11,16 
A recent study suggests that the efficacy of ulipristal acetate may rapidly decline with increasing 
body mass index (BMI), beginning at a BMI of 35, or roughly 194 pounds.6,8 Until further evidence 
becomes available:
 •Women who weigh over 165 pounds, or who are likely to ovulate soon may be advised that ella®  
is the most effective pill regimen available, and that emergency IUD insertion may also  
be considered.6,8
 •Women who weigh over 194 pounds or have a BMI of 35 or over may be advised that when clinically 
appropriate, emergency IUD insertion is recommended as the most effective type of EC available.6,8
It is not known whether use of ulipristal acetate, a progesterone agonist/antagonist, may briefly decrease the 
effectiveness of a woman’s regular progestin-containing hormonal birth control method (like the pill, ring, 
or patch). Therefore, women who choose ulipristal acetate for EC should be advised to abstain 
from sex or to use a barrier birth control method (such as a condom) until the start of their next 
menstrual cycle regardless of whether or not an ongoing hormonal method of birth control  
is used.10  
Dosing: 30 mg ulipristal acetate by mouth within 120 hours (5 days) after sexual assault or rape.6,10,11,16
Note: More research is needed to learn if pregnant and breastfeeding women can safely use ella®. Patients who are 
unsure of their pregnancy status prior to the assault should be advised to take a pregnancy test before choosing ella®.10
Two types of EC pills have been approved by the U.S. Food and Drug 
Administration (FDA):    
1.
This legislatively-mandated, medically, and factually accurate fact sheet prepared by Massachusetts Department of Public  
Health (pursuant to M.G.L. c. 111, § 70E) reflects current medical research and standard of practice (revised March, 2014).  
See www.mass.gov/emergencycontraception for a full text version of the law and other related resources.
Page 4 / 6
Several daily combined estrogen/progestin oral contraceptive pills (OCPs) have been determined  
by the FDA to be safe and effective for off-label use as EC when taken in higher doses.22 While some women may benefit  
from learning how to use OCPs for EC in the future when other options are not available, this method is not only less  
effective, but also increases the likelihood of experiencing side effects (like nausea and vomiting), making OCPs the least  
desirable option for most women following sexual assault. Dosing varies by type of OCP.1,6,22 More information on these  
regimens is available at www.mariatalks.com/ec-birth-control-pills.
Progestin-only pills: Plan B One-Step®, and generic equivalents such as Next Choice™, MyWay™, and  
Levonorgestrel are FDA-approved EC pills that contain progestin, a hormone found in many daily birth control  
pills. Plan B One-Step® is currently the only non-prescription EC product available for purchase by  
anyone (without age restrictions) at pharmacy shelves or counters, although generic versions may soon  
be available without age restrictions.
The FDA has approved progestin-only EC pills to be initiated up to 72 hours (3 days) after unprotected  
sex (or sexual assault); however, research has shown progestin-only EC pills to be effective when  
initiated up to 120 hours (5 days) after sex.17,18
About seven of eight pregnancies (88%) can be prevented with timely use of progestin-only EC pills.9  
 •Progestin-only pills reduce pregnancy risk by 87–90% if taken within 72 hours of unprotected sex.  
If taken between 72–120 hours, they reduce pregnancy risk by 72–87%.18
Patients should be informed that progestin-only EC pills are more effective the sooner they are taken. 
 •For every 12 hours that a woman delays initiation, her chances of becoming pregnant increase  
by almost 50%.19 
A recent study suggests that progestin-only pills may not be effective in women weighing over 175 pounds, 
as the efficacy of progestin-only pills appears to rapidly decline with increasing body mass index 
(BMI), beginning at a BMI of 26 (or roughly 165 pounds).6,8  Until further evidence becomes available:
 •Women who weigh over 165 pounds, or who are likely to ovulate soon may be advised that ella® is  
the most effective pill regimen available, and that emergency IUD insertion may also be considered.6,8
 •Women who weigh over 194 pounds or have a BMI of 35 or over may be advised that when clinically 
appropriate, emergency IUD insertion is recommended as the most effective type of EC available.6,8
Using progestin-only EC pills will not affect a woman’s ability to become pregnant in the future.5  
If progestin-only EC pills are taken when a woman is pregnant, or if pregnancy occurs despite use, they will not 
cause an abortion or harm the developing fetus.3,5,9,10,20,21
Dosing: 1.5 mg levonorgestrel by mouth as soon as possible within 120 hours (5 days) after sexual assault  
or rape. (If a two-dose regimen is used, both pills may be taken at once).1,2,5,9,11 
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Medical follow-up after taking EC pills 
for sexual assault or rape survivors
Patient should be instructed to contact a medical 
provider immediately if she vomits within 2-3 hours  
of EC administration. A repeat dose may be advised.9,10
If patient experiences severe lower abdominal pain  
3-5 weeks after EC administration, she should be  
evaluated for ectopic pregnancy.9,10
If menstruation does not occur within 4 weeks of  
EC administration, a pregnancy test is indicated.13 
If patient declined EC, she should be advised to  
have a pregnancy test 10 days after the ED visit.13
Patients should be advised to use a back-up birth 
control method if possible, such as a condom until  
the start of the next menses. 
A regular hormonal contraception method can be 
initiated or resumed immediately after taking  
progestin-only EC or combined OCPs, or at the start  
of the next menses after taking ulipristal acetate.10
EC does not prevent transmission of sexually  
transmitted infections (STI) or HIV.9,10 Concerned  
patients should be counseled about the risks  
and benefits of STI and HIV prophylaxis. 
Additional Support Services
 
Rape Crisis Centers can refer survivors in need of 
ongoing services: Contact 1-800-841-8371 (English)  
or 1-800-233-5001 (Spanish) or  
www.surviverape.org.
MDPH Family Planning Programs provide 
confidential, low-cost reproductive health care  
services sensitive to the needs of survivors.  
Contact 617-624-6060 or  
www.mariatalks.com/find-services.
Massachusetts Department of Public Health 
Division of Health Care Quality can assist  
survivors (or hospital staff) in lodging a formal 
complaint if the reason EC was not provided in the  
ED was not medically accurate or based on best  
clinical practice. Contact 1-800-462-5540.
In the future, survivors can access EC at a clinic, 
pharmacy or search online. Massachusetts  
pharmacists trained to dispense EC without a  
prescription to all women, including those under  
the age of 17 or who lack a valid ID, can be located  
at www.mariatalks.com/ec-pharmacies.
National Clinician’s Post Exposure Prophylaxis 
Hotline can assist providers in urgent decision-making 
following exposures to HIV and hepatitis B and C at 
1-888-448-4911 from 9am-2am EST (daily).
